Carolyn E. Taylor

CIK: 0001875324

Transaction Breakdown

Open Market Buys (P)2 (50.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

TNXP

Tonix Pharmaceuticals Holding Corp.

Director

Discretionary Trading P&L

Holdings

Transaction History (4 total)

TNXP
Tonix Pharmaceuticals Holding Corp.
Jun 12, 2026
Purchase(P)
Direct
1.4K shares at avg. $10.55$15K
TNXP
Tonix Pharmaceuticals Holding Corp.
May 12, 2026
Award(A)
Stock Option
Direct
22.7K shares-
TNXP
Tonix Pharmaceuticals Holding Corp.
Aug 21, 2025
Purchase(P)
Direct
418 shares at avg. $36.03$15K
TNXP
Tonix Pharmaceuticals Holding Corp.
May 13, 2025
Award(A)
Stock Option
Direct
10K shares-

		Type	Shares	Price		Ownership
Jun 12, 2026	TNXP Tonix Pharmaceuticals Holding Corp.	Purchase(P)	1,415	$10.55	$14,928	Direct
May 12, 2026	TNXP Tonix Pharmaceuticals Holding Corp.	Award(A) Stock Option	22,700	-	-	Direct
Aug 21, 2025	TNXP Tonix Pharmaceuticals Holding Corp.	Purchase(P)	418	$36.03	$15,061	Direct
May 13, 2025	TNXP Tonix Pharmaceuticals Holding Corp.	Award(A) Stock Option	10,000	-	-	Direct

1-4 of 4 transactions

About Taylor Carolyn E.

Taylor Carolyn E. (SEC CIK 0001875324) files insider reports with the SEC as Director of Tonix Pharmaceuticals Holding Corp. (TNXP).

Signal8 holds 4 ownership filings by Taylor Carolyn E., all Form 4s, filed between May 15, 2025 and Jun 15, 2026. Those filings report 4 transactions, from May 13, 2025 to Jun 12, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Taylor Carolyn E.'s filings is in BERKELEY HEIGHTS, NJ.

Recent filings by Taylor Carolyn E.

Jun 12, 2026: Open-market purchase of TNXP shares (Form 4, code P).
May 12, 2026: Grant or award of TNXP derivative securities (Form 4, code A).
Aug 21, 2025: Open-market purchase of TNXP shares (Form 4, code P).
May 13, 2025: Grant or award of TNXP derivative securities (Form 4, code A).

Other insiders filing for Tonix Pharmaceuticals Holding Corp. (TNXP)

Englese Thomas, Chief Commercial Officer
BAGGER RICHARD H, Director
SAENGER BRADLEY, Chief Financial Officer
Stillwell Richard Newcomb, Director
LEDERMAN SETH, Chief Executive Officer
OLUKOTUN ADEOYE Y, Director

How to read Form 4 transaction codes